AN2 Therapeutics (ANTX) Retained Earnings (2021 - 2026)
AN2 Therapeutics (ANTX) reported Retained Earnings of -$5000.0 for Q1 2026, up 100.0% year-over-year from -$2500.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$241.0 million in Q4 2025.
AN2 Therapeutics (ANTX) Retained Earnings (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Retained Earnings data on file, last reported at -$5000.0 in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$5000.0, up 100.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5000.0 (up 100.0% YoY), and the FY2025 annual result was -$241.0 million, down 777519.35% from the prior year.
- Retained Earnings advanced to -$5000.0 in Q1 2026 per ANTX's latest filing, from -$241.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $275000.0 in Q4 2023 and troughed at -$241.0 million in Q4 2025.
- A 5-year average of -$91.6 million and a median of -$77.9 million in 2022 frame the typical range for Retained Earnings.
- On a YoY basis, Retained Earnings climbed as much as 192.59% in 2025 and fell as far as 777519.35% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$374000.0 in 2022, then jumped by 173.53% to $275000.0 in 2023, then slumped by 88.73% to $31000.0 in 2024, then tumbled by 777519.35% to -$241.0 million in 2025, then soared by 100.0% to -$5000.0 in 2026.
- Business Quant data shows ANTX's Retained Earnings at -$5000.0 in Q1 2026, -$241.0 million in Q4 2025, and -$232.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | -838.07 Mn |
| 10 | AN2 Therapeutics | 165.87 Mn | 165.87 Mn | - | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | -241.00 Mn |
| Sep 30, 2025 | -232.24 Mn |
| Jun 30, 2025 | 25,000.00 |
| Mar 31, 2025 | -216.43 Mn |
| Dec 31, 2024 | 31,000.00 |
| Sep 30, 2024 | -198.25 Mn |
| Jun 30, 2024 | -27,000.00 |
| Mar 31, 2024 | -171.07 Mn |
| Dec 31, 2023 | 275,000.00 |
| Sep 30, 2023 | -137.56 Mn |
| Jun 30, 2023 | -120.85 Mn |
| Mar 31, 2023 | -105.05 Mn |
| Dec 31, 2022 | -374,000.00 |
| Sep 30, 2022 | -77.88 Mn |
| Jun 30, 2022 | -360,000.00 |
| Mar 31, 2022 | -56.42 Mn |
| Dec 31, 2021 | -47.38 Mn |